Compare FGNX & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGNX | BYSI |
|---|---|---|
| Founded | 1932 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 35.8M |
| IPO Year | 2014 | 2016 |
| Metric | FGNX | BYSI |
|---|---|---|
| Price | $7.54 | $0.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | 107.2K | ★ 2.0M |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,023,000.00 | N/A |
| Revenue This Year | $650.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.70 | N/A |
| 52 Week Low | $1.59 | $0.67 |
| 52 Week High | $15.10 | $2.44 |
| Indicator | FGNX | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 30.83 |
| Support Level | $5.64 | N/A |
| Resistance Level | $7.71 | $1.30 |
| Average True Range (ATR) | 0.76 | 0.11 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 63.89 | 5.87 |
FG Nexus Inc operates through two primary segments: Digital Assets and Merchant Banking, with Digital Assets contributing the majority of revenue. The Company functions as a digital asset treasury, mainly holding Ethereum (ETH) and exploring opportunities in the tokenization of real-world assets, leveraging ETH as the foundation for digital finance, stablecoins, DeFi, and tokenized assets. The Merchant Banking segment offers strategic, administrative, and regulatory support to newly formed SPACs through the Company's SPAC platform.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.